A global executive at F. Hoffman-La Roche delivered insights into the complex emerging market for biosimilars at an INFORMS conference held recently in Las Vegas.
Jenn Bonilla PhD, Global Head of Business Insights, Operations, and Established Products at F. Hoffman-La Roche Ltd., discussed the entrance of new competition from biosimilars and the challenge of predicting business impact to inform strategic decisions and planning. Dr. Bonilla was joined by co-presenter Ritske van der Meer, a senior engagement manager at Strategic Decisions Group (SDG) who supported the analysis at Roche.
Their presentation, “Pharmaceutical Decision Making in the World of Biosimilars,” was featured in the 2017 Business Analytics Conference of INFORMS, an international society for practitioners in the fields of operations research and management science.
Biologic drugs have revolutionized the treatment of many diseases, and biosimilars are follow-on products highly similar to approved biologics. Biosimilars have been approved for immunology and are expected for cancer treatment soon. As biosimilar competition emerges, it is unclear how physicians, payers, and patients will adopt biosimilars in place of biologics.
In their analysis, Dr. Bonilla and van der Meer used probabilistic analysis instead of conventional scenario models to identify sources of value and risk and produce insights for decision making.